TPO and myelofibrosis: This stands in contrast to the documented side effects associated with other approved TPO-RAs, such as romiplostim, eltrombopag, and avatrombopag, where incidences of thromboembolic events, hepatotoxicity, cataracts, prolonged QT intervals, and myelofibrosis have been noted [5].